10/590400 'AP9 Rec'd PCT/PTO 23 AUG 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BARBARA WOLFF-WINISKI

INTERNATIONAL APPLICATION NO: PCT/EP2005/002015

FILED: 25 FEBRUARY 2005

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: SCREENING ASSAY FOR MODULATORS OF INTERACTION

BETWEEN INTERLEUKIN-12 AND/OR -23 WITH THEIR

RECEPTORS

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/002015, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7909

Date: August 22, 2006

Thomas R. Savitsky Attorney for Applicant

Reg. No. 31,661

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AP9 Rec'd PCT/P10.23 AUG 2006

33658-US-PCT
APPLICATION NO.
Not Yet Known
APPLICANT
Barbara Wolff-Winiski
FILING DATE
Herewith

Group

			0.5.	PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
	AA	5,853,721	12/29/98	Gately et al.				
	AB	5,861,279	1/19/99	Zhang et al.				
	AC	6,338,848	1/15/02	Leonard et al.				_
	AD							
	AE							
	AF							- 12
	AG							
	АН							
	Al							
	AJ							
	AK							
	AL							
			FOREIC	ON PATENT DOCUMENTS				
		T	T	T	T		TDAN	CL ATION
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS		SLATION NO
	AM	1 243 597	9/25/02	OFFICE EP	CLASS	SUBCLASS	YES	NO D
	AM AN			<u> </u>	CLASS	SUBCLASS		
		1 243 597	9/25/02	EP	CLASS	SUBCLASS	YES	NO
	AN	1 243 597 1 179 348	9/25/02 2/13/02	EP EP	CLASS	SUBCLASS	YES	NO
	AN AO	1 243 597 1 179 348 00/36103	9/25/02 2/13/02 6/22/00	EP EP WO	CLASS	SUBCLASS	YES	NO
	AN AO AP	1 243 597 1 179 348 00/36103 97/26332 01/05974	9/25/02 2/13/02 6/22/00 7/24/97 1/25/01	EP EP WO WO WO			YES	NO
	AN AO AP	1 243 597 1 179 348 00/36103 97/26332 01/05974	9/25/02 2/13/02 6/22/00 7/24/97 1/25/01	EP EP WO WO WO (Including Author, Title, Date, Pertine	ent pages, E	itc.)	YES	NO
	AN AO AP	1 243 597 1 179 348 00/36103 97/26332 01/05974 OTHER DOO Parham et al., "A Rec Cytokine Receptor Sc	9/25/02 2/13/02 6/22/00 7/24/97 1/25/01 SUMENTS septor for the	EP WO WO (Including Author, Title, Date, Pertine Heterodimeric Cytokine IL-23 i R", Journal of Immunology, Vol.	ent pages, E s Compos 168, pp.	etc.) sed of IL-12R 5699-5708 (2	TES	NO
	AN AO AP AQ	1 243 597 1 179 348 00/36103 97/26332 01/05974 OTHER DOO Parham et al., "A Rec Cytokine Receptor Sc	9/25/02 2/13/02 6/22/00 7/24/97 1/25/01 EUMENTS eeptor for the Jubunit, IL-23	EP EP WO WO (Including Author, Title, Date, Pertine et Heterodimeric Cytokine IL-23 i R", Journal of Immunology, Vol.	ent pages, E s Compos 168, pp.	etc.) sed of IL-12R 5699-5708 (2	TES	NO
	AN AO AP AQ AR	1 243 597 1 179 348 00/36103 97/26332 01/05974 OTHER DOO Parham et al., "A Rec Cytokine Receptor Sc Oppmann et al., "Nov IL-12", Immunity, Vol. Belladonna et al., "IL-	9/25/02 2/13/02 6/22/00 7/24/97 1/25/01 EUMENTS Eeptor for the abunit, IL-23 rel p19 Prote 13, No. 5, p	EP EP WO WO (Including Author, Title, Date, Pertine et Heterodimeric Cytokine IL-23 i R", Journal of Immunology, Vol.	ent pages, E s Compos 168, pp.	sed of IL-12R 5699-5708 (2	TES I and a coop.	NO D D D D D D D D D D D D D D D D D D
EXAMINE	AN AO AP AQ AR AR	1 243 597 1 179 348 00/36103 97/26332 01/05974 OTHER DOO Parham et al., "A Rec Cytokine Receptor Sc Oppmann et al., "Nov IL-12", Immunity, Vol. Belladonna et al., "IL-	9/25/02 2/13/02 6/22/00 7/24/97 1/25/01 EUMENTS Eeptor for the abunit, IL-23 rel p19 Prote 13, No. 5, p	EP EP WO WO (Including Author, Title, Date, Pertine e Heterodimeric Cytokine IL-23 i R", Journal of Immunology, Vol. ein Engages IL-12p40 to FOrm a pp. 715-725 (2000).	ent pages, E s Compos 168, pp.	sed of IL-12R 5699-5708 (2	TES I and a coop.	NO D D D D D D D D D D D D D D D D D D

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

10/590400 APPRECIPITIO²23 AUG 2006 33658-US-PCT

33658-US-PCT
APPLICATION NO.
Not Yet Known
APPLICANT
Barbara Wolff-Winiski
FILING DATE
Herewith

Group

			U.S. 1	PATENT D	OCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILI	NG DATE
	ВА								
	вв				-				
	вс								
	BD		-						
	BE				_				
	BF								
	BG								
	вн								
	ВІ								
	BJ								
	вк								
	BL								
	1		FOREIG	N PATENT	DOCUMENTS				
		DOCUMENT NUMBER	DATE		OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
-	ВМ	02/095414	11/28/02	wo					
	DIVI	02/030414							
	BN	02/030414							
		02.000414							
	BN	02.000414						=-	+=
	BN BO	02.000414							+=
	BN BO BP		UMENTS (Including Au	thor, Title, Date, Pertine	ent pages, E	tc.)		
	BN BO BP		ole of IL-23 i						
	BN BO BP BQ	OTHER DOC Benson et al., "The Ro	ole of IL-23 i 45 (2002).	n Experime	ental Autoimmune Ei	ncephalon	nyelitil", FASE	B Jou	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
	BN BO BP BQ	OTHER DOC Benson et al., "The Ro Vol. 16, No. 5, p. A104	ole of IL-23 i 45 (2002).	n Experime	ental Autoimmune Ei	ncephalon	nyelitil", FASE	B Jou	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.